When it comes to protecting chronically ill patients over healthcare special interests, you’d think that Assemblyman Mike Gatto (D-Burbank) would be on our side. However, recent legislation, which passed overwhelmingly in the state Legislature with bipartisan support, has suddenly stalled in his Assembly Appropriations Committee.
[Editor's Note: The writer revised his opinion in a later letter. See: "Oops. He had incorrect information."]
The delivery of optimal health care for patients is constantly evolving and recent developments are some of the most profound I’ve witnessed in my career. However, these futuristic changes are also bringing consequences of concern related to patient safety.
Innovative, scientific advancements have led to the creation of more effective prescription drugs. Biologics are now being created from living organisms to treat cancer, HIV/AIDS, MS, Parkinson’s and many other debilitating illnesses with remarkable results. These advanced drugs contain an incredibly high level of molecular complexity. And unlike chemical drugs, there is no generic form of a biologic. Biosimilars aim to replicate — they are not the same and are not generic because do not utilize the same living cell line, production process, or raw material as the biologic.